BioSpace News Archive

IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced new evidence that decentralized clinical trials (DCT) deliver measurable benefits for patients, sites and sponsors.

Exscientia announced that Company management will participate in the following investor conferences in September.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that full results from the CONNECT1 study evaluating the ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and the Digihaler System in the management of asthma patients compared to standard of care (SoC) albuterol reliever therapy, were published online ahead of print in The Journal of Allergy and Clinical Immunology: In Practice.

Dermavant Sciences announced the company has been named one of the 2022 Best Small Workplaces™ and 2022 Best Workplaces in Biopharma™ by Fortune magazine and Great Place to Work® — Dermavant’s fourth and fifth recognitions by the organizations.

Zenas BioPharma announced the appointment of Simon Lowry, M.D., as the company’s Chief Medical Officer.

Outlook Therapeutics, Inc. announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that company management will participate in the following upcoming investor conferences in September.

Recce Pharmaceuticals Ltd is pleased to announce the appointment of Alistair McKeough to its Board of Directors.

Tempest Therapeutics, Inc. announced that Stephen R. Brady, chief executive officer of Tempest, will present at the H.C. Wainwright 24th Annual Global Investment Conference.

Candel Therapeutics, Inc. announced that Jason A. Amello, has been named as the Company’s Chief Financial Officer and Garrett Nichols, MD, MS, has been named as the Company’s Chief Medical Officer.